Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what assessment his Department has made of the effect of the Cystic Fibrosis Trust's proposal for collaboration between the NHS and Vertex to widen access to the treatment Orkambi on the treatment of the patients with that disease.

The Department has received the Cystic Fibrosis Trust’s proposals for an arrangement that would potentially allow access to Orkambi (lumacaftor in combination with ivacaftor) as part of a Managed Access Scheme in the National Institute for Health and Care Excellence’s (NICE) appraisal of Orkambi.

I have encouraged the Trust and the manufacturer, Vertex Pharmaceuticals, to engage with NICE to consider whether there remains scope for this, or any other, proposal to be taken into account in its appraisal and the Department is also engaging with the manufacturer directly on this matter.